tiprankstipranks
Trending News
More News >

SSY Group’s Allopurinol Gains Approval for Market Release

Story Highlights
SSY Group’s Allopurinol Gains Approval for Market Release

Confident Investing Starts Here:

SSY Group ( (HK:2005) ) has shared an announcement.

SSY Group Limited has announced that its product, Allopurinol, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This development marks a significant step in the company’s product offerings, particularly in the treatment of gout and high uric acid, potentially enhancing its position in the pharmaceutical market.

More about SSY Group

SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company is involved in creating treatments for various health conditions, with a market focus on pharmaceuticals.

YTD Price Performance: -10.39%

Technical Sentiment Signal: Buy

Current Market Cap: $1.15B

For an in-depth examination of 2005 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App